Climb Bio, Inc. CLYM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Climb Bio, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Climb Bio, Inc.'s cash & equivalents?
- Climb Bio, Inc. (CLYM) reported cash & equivalents of $8.36M in Q1 2026.
- How has Climb Bio, Inc.'s cash & equivalents changed year-over-year?
- Climb Bio, Inc.'s cash & equivalents decreased by 71.2% year-over-year, from $29.02M to $8.36M.
- What is the long-term trend for Climb Bio, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s cash & equivalents has grown at a 11.7% compound annual growth rate (CAGR), from $20.49M to $35.69M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.